分子靶向药物索拉非尼治疗晚期肝细胞癌的疗效 - Suppr

Suppr

超能文献

Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.

作者信息

Kuzuya Teiji, Tsuchiya Kaoru, Izumi Namiki

机构信息

Divisions of Gastroenterology and Hepatologym, Musashino Red Cross Hospital, Tokyo

出版信息

Gan To Kagaku Ryoho. 2010 Oct;37(10):1883-86.

PMID:21069944

Abstract

摘要

相似文献

Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.

Gan To Kagaku Ryoho. 2010 Oct;37(10):1883-86.

[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].

Gastroenterol Clin Biol. 2008 Jan;32(1 Pt. 1):3-7. doi: 10.1016/j.gcb.2007.11.001. Epub 2008 Mar 4.

Sorafenib in hepatocellular carcinoma: separating the hype from the hope.

J Clin Oncol. 2008 Dec 20;26(36):5845-8. doi: 10.1200/JCO.2008.19.7996. Epub 2008 Nov 24.

Sorafenib: delivering a targeted drug to the right targets.

Expert Rev Anticancer Ther. 2007 May;7(5):617-26. doi: 10.1586/14737140.7.5.617.

Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.

Oncology. 2010 Jul;78 Suppl 1:154-66. doi: 10.1159/000315245. Epub 2010 Jul 8.

Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.

Oncology. 2010 Jul;78 Suppl 1:167-71. doi: 10.1159/000315246. Epub 2010 Jul 8.

Systemic treatment of hepatocellular carcinoma: dawn of a new era?

Ann Surg Oncol. 2010 May;17(5):1247-56. doi: 10.1245/s10434-010-0975-6. Epub 2010 Apr 20.

Sorafenib: new indication. For some patients with liver cancer.

Prescrire Int. 2009 Apr;18(100):59.

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.

Expert Opin Investig Drugs. 2010 May;19(5):663-72. doi: 10.1517/13543781003767426.

Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.

Expert Opin Pharmacother. 2010 Sep;11(13):2187-98. doi: 10.1517/14656561003724705.

引用本文的文献

MARK1 suppress malignant progression of hepatocellular carcinoma and improves sorafenib resistance through negatively regulating POTEE.

Open Med (Wars). 2024 Nov 7;19(1):20241060. doi: 10.1515/med-2024-1060. eCollection 2024.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.

作者信息

Kuzuya Teiji, Tsuchiya Kaoru, Izumi Namiki

机构信息

Divisions of Gastroenterology and Hepatologym, Musashino Red Cross Hospital, Tokyo

出版信息

Gan To Kagaku Ryoho. 2010 Oct;37(10):1883-86.

PMID:21069944

Abstract

摘要

相似文献

Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.

Gan To Kagaku Ryoho. 2010 Oct;37(10):1883-86.

[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].

Gastroenterol Clin Biol. 2008 Jan;32(1 Pt. 1):3-7. doi: 10.1016/j.gcb.2007.11.001. Epub 2008 Mar 4.

Sorafenib in hepatocellular carcinoma: separating the hype from the hope.

J Clin Oncol. 2008 Dec 20;26(36):5845-8. doi: 10.1200/JCO.2008.19.7996. Epub 2008 Nov 24.

Sorafenib: delivering a targeted drug to the right targets.

Expert Rev Anticancer Ther. 2007 May;7(5):617-26. doi: 10.1586/14737140.7.5.617.

Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.

Oncology. 2010 Jul;78 Suppl 1:154-66. doi: 10.1159/000315245. Epub 2010 Jul 8.

Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.

Oncology. 2010 Jul;78 Suppl 1:167-71. doi: 10.1159/000315246. Epub 2010 Jul 8.

Systemic treatment of hepatocellular carcinoma: dawn of a new era?

Ann Surg Oncol. 2010 May;17(5):1247-56. doi: 10.1245/s10434-010-0975-6. Epub 2010 Apr 20.

Sorafenib: new indication. For some patients with liver cancer.

Prescrire Int. 2009 Apr;18(100):59.

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.

Expert Opin Investig Drugs. 2010 May;19(5):663-72. doi: 10.1517/13543781003767426.

Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.

Expert Opin Pharmacother. 2010 Sep;11(13):2187-98. doi: 10.1517/14656561003724705.

引用本文的文献

MARK1 suppress malignant progression of hepatocellular carcinoma and improves sorafenib resistance through negatively regulating POTEE.

Open Med (Wars). 2024 Nov 7;19(1):20241060. doi: 10.1515/med-2024-1060. eCollection 2024.